Skip to main content
. 2022 Oct 5;556:111296. doi: 10.1016/j.jtbi.2022.111296

Fig. 8.

Fig. 8

Observed numbers with antibodies to SARS-CoV-2, from the national commercial laboratory (Anti-N) or blood donor (Anti-S or Anti-N) seroprevalence study, and predicted numbers temporarily immune (Removed) from simulations with (A and B) and without (C and D) vaccination on 25 December 2020 (A and C) and 4 April 2021 (B and D). Vaccination had no discernible impact on 25 December 2020 serology.